Correlation of Molecular Tumor Markers CA125, HE4, and CEA with the Development and Progression of Epithelial Ovarian Cancer
Background: This study was designed to explore the levels of serum moleculartumor markers carbohydrate antigen 125 (CA125), human epididymis protein 4 (HE4), and carcinoembryonic antigen (CEA) in patients with primary epithelial ovarian cancer, and their correlation with the progression of the cancer.
Methods: A total of 222 people were enrolled in this study admitted to Jining Maternal and Child Health and Family Planning Service Center from January 2016 to December 2017. There were 122 patients with primary epithelial ovarian cancer (ovarian cancer group), 50 patients with benign ovarian diseases (benign control group), and 50 healthy individuals (normal control group). The levels of serum CA125, CEA, and HE4 were detected by the electrochemical luminescence method and ELISA.
Results: The levels of serum CA125, HE4, and CEA in the ovarian cancer group were significantly higher than those in patients with the benign control group and the normal control group (P<0.01). The levels of serum CA125, HE4, and CEA in the high clinical staging group (stage III and stage II), low differentiation group, comorbid ascites group, metastasis group, and recurrence group were significantly higher than those in the low clinical staging group (stage I and stage II), high + moderate differentiation group, non-ascites group, non-metastasis group, and non-recurrence group, respectively (all P<0.05), and the levels of serum CA125, HE4, and CEA decreased significantly after treatment (P<0.01).
Conclusion: The levels of serum CA125, HE4, and CEA are closely related to the development and progression of epithelial ovarian cancer, and combined detection of CA125, HE4 and CEA is of great significance for early diagnosis, disease development monitoring, and prognosis evaluation of epithelial ovarian cancer.
2. Li PL, Zhang X, Li TF et al (2015). Com-bined detection of sialic acid and hydrox-yproline in diagnosis of ovarian cancer and its comparison with human epidi-dymis protein 4 and carbohydrate antigen 125. Clin Chim Acta, 439: 148-153.
3. Su Z, Graybill WS, Zhu Y (2013). Detection and monitoring of ovarian cancer. Clin Chim Acta, 415: 341-345.
4. Yang ZJ, Zhao BB, Li L (2016). The signifi-cance of the change pattern of serum CA125 level for judging prognosis and diagnosing recurrences of epithelial ovari-an cancer. J Ovarian Res, 9(1): 57.
5. Sandri MT, Bottari F, Franchi D et al (2013). Comparison of HE4,CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outeome. Gyneeol Oncol, 128(2): 233-238.
6. Al-Musalhi K, Al-Kindi M, Ramadhan F, et al (2015). Validity of cancer antigen-125 (CA-125) and risk of malignancy in-dex(rmi) in the diagnosis of ovarian can-cer. Oman Med J, 30(6): 428-434.
7. Narasimhulu DM, Khoury-Collado F, Chi DS (2015). Radical surgery in ovarian cancer. Curr Oncol Rep, 17(4): 16.
8. Bast RC Jr, Badgwell D, Lu Z et al (2005). New tumor markers: CA125 and beyond. Int J Gynecol Cancer, 15 Suppl 3: 274-281.
9. Zheng LE, Qu JY, He F (2016). The diag-nosis and pathological value of combined detection of HE4 and CA125 for patients with ovarian cancer. Open Med (Wars), 11(1): 125-132.
10. Bandiera E, Zanotti L, Fabricio AS et al (2013). Cancer antigen 125, human epidi-dymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide im-munocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis. Clin Chem Lab Med, 51(9): 1815-1824.
11. Zhang F, Zhang ZL (2015). The diagnostic value of transvaginal sonograph (TVS), color doppler, and serum tumor marker CA125, CEA, and AFP in ovarian cancer. Cell Biochem Biophys, 72(2): 353-357.
12. Moore RG, Brown AK, Miller MC et al (2008). Utility of a novel serum tumor bi-omarker HE4 in patients with endome-trioid adenocarcinoma of the uterus. Gy-necol Oncol, 110(2): 196-201.
13. Stiekema A, Boldingh QJ, Korse CM et al (2015). Serum human epididymal protein 4(HE4) as biomarker for the differentia-tion between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin. Gynecol Oncol, 136(3): 562-566.
14. Jia MM, Deng J, Cheng XL et al (2017). Di-agnostic accuracy of urine HE4 in pa-tients with ovariancancer:A meta-analysis. Oncogene, 8(6): 9660-9671.
15. Wang G, Qin Y, Zhang J et al (2014). Nip-ple Discharge of CA15-3, CA125, CEA and TSGF as a New Biomarker Panel for Breast Cancer. Int J Mol Sci, 15(6): 9546- 9565.
16. Chen Y, Gao SG, Chen JM et al (2015). Se-rum CA242, CA199, CAl25, CEA and TSGF are Biomarkers for the Efficacy and Prognosis of Cryoablation in Pan-creatic Cancer Patients. Cell Biochem Biophys, 71(3): 1287-1291.
|Issue||Vol 50 No 6 (2021)|
|Epithelial ovarian cancer; Carbohydrate antigen Protein|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|